BioWorld

Preclinical characterization and chemical structure of potent and selective PDE10A inhibitor MK-8189 reported

Researchers from Merck & Co. Inc. have disclosed the structure and reported preclinical data for MK-8189, a phosphodiesterase 10A (PDE10A) inhibitor.
Nasdaq

Structure Therapeutics Inc. Advances ACCG-2671 as Lead Oral Amylin-Based Drug Candidate with Promising Preclinical Results

Structure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671, which shows promising preclinical results including potent target engagement ...
Seeking Alpha

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral ...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...